JP2016515130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515130A5 JP2016515130A5 JP2016502323A JP2016502323A JP2016515130A5 JP 2016515130 A5 JP2016515130 A5 JP 2016515130A5 JP 2016502323 A JP2016502323 A JP 2016502323A JP 2016502323 A JP2016502323 A JP 2016502323A JP 2016515130 A5 JP2016515130 A5 JP 2016515130A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- measured
- surface plasmon
- plasmon resonance
- resonance assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010067003 Interleukin-33 Proteins 0.000 claims 55
- 102000017761 Interleukin-33 Human genes 0.000 claims 55
- 239000005557 antagonist Substances 0.000 claims 39
- 238000003556 assay Methods 0.000 claims 24
- 238000010494 dissociation reaction Methods 0.000 claims 23
- 230000005593 dissociations Effects 0.000 claims 23
- 208000027866 inflammatory disease Diseases 0.000 claims 22
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 claims 5
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 241000282693 Cercopithecidae Species 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 101000998136 Mus musculus Interleukin-33 Proteins 0.000 claims 4
- 239000013566 allergen Substances 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 claims 3
- 208000030961 allergic reaction Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000045906 human IL33 Human genes 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- -1 bronchodilator Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000670 ligand binding assay Methods 0.000 claims 1
- 230000002912 lymphogenic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000014232 psoriasis 12 Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 230000002992 thymic effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787121P | 2013-03-15 | 2013-03-15 | |
| US61/787,121 | 2013-03-15 | ||
| US201361819029P | 2013-05-03 | 2013-05-03 | |
| US61/819,029 | 2013-05-03 | ||
| US201361913417P | 2013-12-09 | 2013-12-09 | |
| US61/913,417 | 2013-12-09 | ||
| PCT/US2014/027058 WO2014152195A1 (en) | 2013-03-15 | 2014-03-14 | Il-33 antagonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515130A JP2016515130A (ja) | 2016-05-26 |
| JP2016515130A5 true JP2016515130A5 (cg-RX-API-DMAC7.html) | 2017-03-30 |
| JP6404314B2 JP6404314B2 (ja) | 2018-10-10 |
Family
ID=50513479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502323A Active JP6404314B2 (ja) | 2013-03-15 | 2014-03-14 | Ｉｌ−３３拮抗薬とその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9637535B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968454B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6404314B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150127591A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105007929B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014240101B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2904377C (cg-RX-API-DMAC7.html) |
| EA (1) | EA034834B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL240393B (cg-RX-API-DMAC7.html) |
| MX (1) | MX364591B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014152195A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| KR20150127591A (ko) | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| KR102400060B1 (ko) | 2013-12-26 | 2022-05-19 | 미쓰비시 타나베 파마 코퍼레이션 | 인간 항 il-33 중화 단일클론 항체 |
| SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| US10040859B2 (en) | 2014-04-21 | 2018-08-07 | The Children's Hospital Of Philadelphia | Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody |
| KR102003754B1 (ko) | 2014-07-03 | 2019-07-25 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| NZ728688A (en) | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
| RU2722212C9 (ru) | 2014-08-05 | 2020-07-23 | СиБи ТЕРЕПЬЮТИКС, ИНК. | Анти-pd-l1 антитела |
| US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
| KR20170080604A (ko) | 2014-11-10 | 2017-07-10 | 제넨테크, 인크. | 항-인터류킨-33 항체 및 그것의 용도 |
| EP3265107B1 (en) | 2015-03-02 | 2024-10-02 | 180 Therapeutics LP | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| KR102687412B1 (ko) | 2015-10-06 | 2024-07-24 | 리제너론 파아마슈티컬스, 인크. | 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도 |
| US10927155B2 (en) * | 2015-11-19 | 2021-02-23 | George Mason Research Foundation, Inc. | Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta |
| SG11201805900YA (en) * | 2016-01-14 | 2018-08-30 | Anaptysbio Inc | Inhibition of allergic reaction using an il-33 inhibitor |
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| SG11201808693WA (en) | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| CN106198953B (zh) * | 2016-07-19 | 2018-06-29 | 重庆医科大学 | 白介素-33在制备诊断肺源性急性肺损伤试剂盒中的用途 |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| EP3580240A1 (en) | 2017-02-10 | 2019-12-18 | H. Hoffnabb-La Roche Ag | Anti-tryptase antibodies, compositions thereof, and uses thereof |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| CN110431240A (zh) * | 2017-04-13 | 2019-11-08 | 雷杰纳荣制药公司 | 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制 |
| JP7657440B2 (ja) | 2017-06-12 | 2025-04-07 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート |
| TWI877099B (zh) | 2017-06-26 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 |
| MX2020000228A (es) | 2017-07-06 | 2020-08-10 | Regeneron Pharma | Proceso de cultivo celular para producir una glicoproteina. |
| CN115920041A (zh) | 2017-08-31 | 2023-04-07 | 田边三菱制药株式会社 | 含有il-33拮抗剂的子宫内膜异位症治疗剂 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| CN115925882A (zh) | 2017-12-22 | 2023-04-07 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| CN111655722A (zh) | 2018-01-31 | 2020-09-11 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| AU2019218128A1 (en) | 2018-02-09 | 2020-09-17 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| CA3088906A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CN111868085B (zh) | 2018-03-19 | 2024-11-05 | 瑞泽恩制药公司 | 微芯片毛细管电泳测定法及试剂 |
| IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| JP2021535739A (ja) | 2018-08-27 | 2021-12-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 下流精製でのラマン分光法の使用 |
| KR20210053816A (ko) | 2018-08-30 | 2021-05-12 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 복합체를 특성화하기 위한 방법 |
| EP4220173A3 (en) | 2019-01-16 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| KR20220007586A (ko) | 2019-05-13 | 2022-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | 개선된 경쟁적 리간드 결합 검정 |
| KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| AU2020394428B2 (en) | 2019-11-25 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| AU2021209866B2 (en) | 2020-01-21 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| JP2023516497A (ja) | 2020-03-13 | 2023-04-19 | メドイミューン・リミテッド | Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法 |
| KR20220152262A (ko) | 2020-03-13 | 2022-11-15 | 제넨테크, 인크. | 항-인터루킨-33 항체 및 이의 용도 |
| WO2021204707A1 (en) | 2020-04-06 | 2021-10-14 | Medimmune Limited | Treating acute respiratory distress syndrome with il-33 axis binding antagonists |
| MX2023002417A (es) | 2020-08-31 | 2023-03-22 | Regeneron Pharma | Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina. |
| IL303027A (en) | 2020-11-25 | 2023-07-01 | Regeneron Pharma | Sustained release formulations by creating a non-aqueous membrane emulsion |
| EP4262757A1 (en) | 2020-12-17 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| JP2024503408A (ja) | 2021-01-20 | 2024-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養におけるタンパク質力価の改善方法 |
| AU2022230987A1 (en) | 2021-03-03 | 2023-08-31 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| AU2022243005A1 (en) | 2021-03-26 | 2023-10-05 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| WO2023009975A2 (en) * | 2021-07-24 | 2023-02-02 | Anwita Biosciences, Inc. | Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| KR20240058201A (ko) | 2021-09-20 | 2024-05-03 | 리제너론 파마슈티칼스 인코포레이티드 | 항체 이질성을 제어하는 방법 |
| CN118076885A (zh) | 2021-10-07 | 2024-05-24 | 里珍纳龙药品有限公司 | pH计校准与校正 |
| WO2023059800A2 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| JP2024544885A (ja) | 2021-11-10 | 2024-12-05 | ジェネンテック， インコーポレイテッド | 抗インターロイキン－３３抗体及びその使用 |
| TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
| CN120418653A (zh) | 2022-12-16 | 2025-08-01 | 里珍纳龙药品有限公司 | 评估色谱柱完整性的方法和系统 |
| TW202445135A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 液態蛋白質組成物穩定性之建模方法 |
| EP4655595A1 (en) | 2023-01-25 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| EP4669963A2 (en) | 2023-02-22 | 2025-12-31 | Regeneron Pharmaceuticals, Inc. | SYSTEM FITNESS PARAMETERS AND COLUMN AGING |
| AU2024265540A1 (en) | 2023-05-01 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| TW202532098A (zh) | 2023-09-29 | 2025-08-16 | 美商再生元醫藥公司 | 使用控制成核之冷凍乾燥 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1000056A (en) | 1910-11-03 | 1911-08-08 | Carlos Van Bergh | Threshing-machine. |
| US1001164A (en) | 1911-06-09 | 1911-08-22 | Arthur W Porter | Cotton-sweep. |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US5576191A (en) | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
| US20070042978A1 (en) | 2002-12-19 | 2007-02-22 | Jean-Philippe Girard | Nf-hev compositions and methods of use |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| WO2007140205A2 (en) * | 2006-05-24 | 2007-12-06 | Biogen Idec Ma Inc. | Methods of treating fibrosis |
| AT502353B1 (de) | 2006-06-29 | 2007-07-15 | Avl List Gmbh | Verfahren und vorrichtung zur konditionierung eines o2-hältigen gases |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| CA2685124A1 (en) | 2007-04-26 | 2008-11-06 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided T Rinity Of Queen Elizabeth Near Dublin | Products for altering il-33 activity and methods therefor |
| WO2008144610A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
| JP2011500748A (ja) | 2007-10-26 | 2011-01-06 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 神経変性障害の治療におけるｃａｓｐａｓｅＩ−依存性サイトカインの阻害剤 |
| MX348362B (es) * | 2008-03-31 | 2017-06-07 | Genentech Inc * | Composiciones y metodos para tratar y diagnosticar asma. |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| KR20150127591A (ko) | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| KR102400060B1 (ko) | 2013-12-26 | 2022-05-19 | 미쓰비시 타나베 파마 코퍼레이션 | 인간 항 il-33 중화 단일클론 항체 |
| SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
-
2014
- 2014-03-14 KR KR1020157022680A patent/KR20150127591A/ko not_active Abandoned
- 2014-03-14 EA EA201591331A patent/EA034834B1/ru not_active IP Right Cessation
- 2014-03-14 JP JP2016502323A patent/JP6404314B2/ja active Active
- 2014-03-14 CA CA2904377A patent/CA2904377C/en active Active
- 2014-03-14 MX MX2015011408A patent/MX364591B/es active IP Right Grant
- 2014-03-14 CN CN201480013599.0A patent/CN105007929B/zh not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/027058 patent/WO2014152195A1/en not_active Ceased
- 2014-03-14 EP EP14718264.6A patent/EP2968454B1/en active Active
- 2014-03-14 AU AU2014240101A patent/AU2014240101B2/en active Active
- 2014-03-14 US US14/210,599 patent/US9637535B2/en active Active
-
2015
- 2015-08-06 IL IL240393A patent/IL240393B/en active IP Right Grant
-
2017
- 2017-03-20 US US15/463,910 patent/US10011647B2/en active Active
-
2018
- 2018-05-29 US US15/991,763 patent/US10774128B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515130A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513644A5 (cg-RX-API-DMAC7.html) | ||
| Vatrella et al. | Dupilumab: a novel treatment for asthma | |
| Kasaian et al. | IL-13 as a therapeutic target for respiratory disease | |
| Legrand et al. | Biologic therapies targeting eosinophils: current status and future prospects | |
| HRP20200846T1 (hr) | Anti-il-33 antitijela i njihove primjene | |
| Plichta et al. | Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives | |
| JP2018533557A5 (cg-RX-API-DMAC7.html) | ||
| Menzella et al. | Tailored therapy for severe asthma | |
| JP2020513404A (ja) | 炎症性状態の処置方法 | |
| JP2016529232A (ja) | サイトカインアンタゴニストの標的化 | |
| JP2020513404A5 (cg-RX-API-DMAC7.html) | ||
| Heck et al. | Pharmacological therapy of bronchial asthma: the role of biologicals | |
| JP2016539096A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533888A5 (cg-RX-API-DMAC7.html) | ||
| JP2019116499A (ja) | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 | |
| CN108350069A (zh) | 针对il-23的多肽 | |
| JP2011520989A5 (cg-RX-API-DMAC7.html) | ||
| Moore et al. | Update in asthma 2009 | |
| JP2011523849A5 (cg-RX-API-DMAC7.html) | ||
| Albrecht | Turning off the alarm–Targeting alarmins and other epithelial mediators of allergic inflammation with biologics | |
| US11156600B2 (en) | Assay for detecting TH1 and TH2 cell populations | |
| Tay et al. | Advances in the treatment of virus-induced asthma | |
| Lemaire et al. | Dual TCR expression biases lung inflammation in DO11. 10 transgenic mice and promotes neutrophilia via microbiota-induced Th17 differentiation | |
| JP2008516985A5 (cg-RX-API-DMAC7.html) |